MedTrace Logo

Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.

NCT00102128 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-05-22

No results posted yet for this study

Summary

Study to examine the safety and effectiveness of implanted skeletal muscle cells (cells removed from the thigh muscle) into scarred areas of heart muscle after heart attack.

Conditions

  • Ischemic Heart Failure
  • Ischemic Heart Disease
  • Ischemic Cardiomyopathy

Interventions

DRUG

Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Genzyme, a Sanofi Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • Belgium
  • France
  • Germany
  • Italy
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00102128 on ClinicalTrials.gov